RDHL RedHill Total Asset Value of Company

RDHL (redhillbio.com) - company brandmark

This chart of exchange quotes on GURU.Markets demonstrates the total assets of RedHill Biopharma (RDHL), which stand at 0.00. RedHill Biopharma (RDHL) leads in the therapy of infections and Crohn's disease, utilizing unique drug combinations to combat resistance. The business is currently optimizing expenses and transferring drug distribution to regional partners. Stable demand for treatment makes this defensive asset resilient to market crises.

RDHL (RedHill Biopharma Ltd.) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company redhillbio.com (RDHL)

- share price and consensus valuation forecast:
Price Chart RedHill Biopharma Ltd.|RDHL - Price Target Chart
- market capitalization data:
Market Valuation RedHill Biopharma Ltd.|RDHL - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share RedHill Biopharma|RDHL - Book Capitalization|Market Capitalization to Book Value Ratio redhillbio.com|RDHL - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio RedHill Biopharma|RDHL - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio RedHill Biopharma Ltd.|RDHL - Company Aggregate Debts|Debts to Book Capitalization RedHill Biopharma Ltd.|RDHL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings RedHill Biopharma|Critical Liquidity redhillbio.com
- net income and valuation multiples indicators:
RDHL - Net Profit
Fundamental valuation:RedHill Biopharma
Manufactured products of RedHill Biopharma Ltd

Driven by exceptional pricing power in GI infection therapy and patents for the drug Talicia, RedHill Biopharma (RDHL) generates high profitability, which, via a reverse ROA calculation, defines the company's asset dynamics as the projected volume of resources available for expansion. Analysis of this chart allows for an assessment of the real cost of capital, stripped of accounting lags and reflecting current efficiency in asset management.

Key competitors

PHAT (phathompharma.com) - Aggregate Company Assets|Aggregate Company Assets Terns Pharmaceuticals, Inc.|Ironwood Pharmaceuticals Inc - Total Asset Value of Company|Company Total Assets CURX|IMRN (immuron.com.au) - Aggregate Asset Value|Company Total Assets EVOK (Evoke Pharma, Inc.)|Company Total Assets Entero Therapeutics Inc. ENTO|PALI - Aggregate Company Assets|Aggregate Asset Value JAGX (Jaguar Health Inc)|Progenity (BIOR) - Aggregate Company Assets|Cumulative Company Assets Morphic Holding Corp